Logo

PerkinElmer Completes $600M Acquisition of Caliper

Nov 09, 2011
Premium

PerkinElmer said this week that it has completed its acquisition of Caliper Life Sciences for around $600 million.

The agreement, which was announced in September, will, among other things, allow PerkinElmer to combine its expertise in informatics with Caliper's automation and sample-prep technology to bolster PerkinElmer's presence in the next-generation sequencing space (IS 9/13/2011).

In a statement, PerkinElmer CEO Robert Friel said that the deal will "strengthen PerkinElmer's position in personalized medicine."

As part of the deal, Caliper CEO Kevin Hrusovsky will join PerkinElmer as president of life sciences and technology to lead a newly created $500 million business that integrates Caliper with PerkinElmer's research business. Hrusovsky said the business will give "customers the tools and insights" to "understand the origins of disease, create new therapies, and transform personalized medicine."

Filed under

Clinical Sequencing
Sequencing
Next-Generation Sequencing
PerkinElmer
Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.